AbCellera Biologics Inc. is a clinical-stage biotechnology company that discovers and develops antibody-based medicines. Based in Vancouver, Canada, the company utilizes an artificial intelligence-powered drug discovery platform to analyze immune systems and identify therapeutic antibodies. Historically operating primarily through a partnership model, AbCellera collaborates with pharmaceutical and biotechnology companies to accelerate drug development in exchange for research fees, milestone payments, and downstream royalties. The company gained significant recognition for its partnership with Eli Lilly to rapidly discover and develop antibody treatments for COVID-19. Recently, AbCellera has transitioned toward advancing its own internal pipeline of proprietary clinical candidates, focusing on therapeutic areas such as endocrinology, women's health, immunology, and oncology. The company also maintains in-house capabilities spanning from early discovery to GMP manufacturing for therapeutic antibodies.
